Death Risks Reduced for Patients on Statins Hospitalised With Influenza: Presented at IDSA
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Death Risks Reduced for Patients on Statins Hospitalised With Influenza: Presented at IDSA

By Ed Susman

PHILADELPHIA -- October 30, 2009 -- Patients on statin therapy who are hospitalised with seasonal influenza have about a 50% reduced risk of dying from the viral infection, researchers stated here at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA).

“This early research suggests a potential role for statins in treatment of influenza and should be studied further,” said Meredith Vandermeer, Emerging Infections Program, Oregon Public Health Division, Portland, Oregon, at a press briefing here October 29.

“This is the first study that looks at the relationship between statins and death among patients hospitalised with influenza,” she said.

Vandermeer and colleagues scrutinised medical records of 2,800 people who were hospitalised with seasonal flu in 10 states during the 2007-2008 influenza season.

In that group of patients, 17 of 801 who were on statins in the hospital (~2.1%) died of influenza or its complications. Of the 1,999 who were not on statins in the hospital, 64 died (~3.2%). Vandermeer said that represented a 54% decreased risk, taking into account other risk factors such as age and use of antiviral drugs.

She said that the database did not allow the researchers to determine the dose of statin that patients were on nor how long the patients had been taking the cholesterol-lowering drugs. She said that the researchers are analysing the data to determine if one brand of statin is associated with better odds of surviving the flu than another.

“We believe that statins may be able to mediate an immune response in addition to being able to lower cholesterol,” she said. However, Vandermeer said the results of the study would not be sufficient to makes recommendations for prescribing statins for treatment of infectious diseases.

“It appears that statins give people some benefit,” said Andrew Pavia, MD, Pediatric Infectious Diseases, University of Utah, Salt Lake City, Utah, who moderated the press briefing for the IDSA.

[Presentation title: Publishing Title: Role of Statins in Preventing Death Among Patients Hospitalized With Lab Confirmed Influenza Infections. Abstract 706]

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities